Fieldview Capital Management LLC Purchases Shares of 20,229 Insmed, Inc. $INSM

Fieldview Capital Management LLC purchased a new stake in Insmed, Inc. (NASDAQ:INSM) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 20,229 shares of the biopharmaceutical company’s stock, valued at approximately $2,913,000.

A number of other institutional investors and hedge funds have also modified their holdings of INSM. EULAV Asset Management bought a new stake in Insmed during the third quarter valued at about $12,961,000. Resolute Capital Asset Partners LLC bought a new position in shares of Insmed in the second quarter worth about $2,748,000. Nisa Investment Advisors LLC lifted its position in shares of Insmed by 374.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock worth $1,507,000 after purchasing an additional 8,261 shares during the last quarter. Keybank National Association OH boosted its stake in Insmed by 76.7% during the 3rd quarter. Keybank National Association OH now owns 16,716 shares of the biopharmaceutical company’s stock valued at $2,407,000 after purchasing an additional 7,257 shares during the period. Finally, Artisan Partners Limited Partnership boosted its stake in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after purchasing an additional 1,623,342 shares during the period.

Insider Buying and Selling at Insmed

In related news, COO Roger Adsett sold 791 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total value of $123,530.47. Following the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at $16,680,517.70. The trade was a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Sara Bonstein sold 748 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total transaction of $116,942.32. Following the completion of the transaction, the chief financial officer directly owned 79,758 shares of the company’s stock, valued at $12,469,365.72. This trade represents a 0.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 189,651 shares of company stock valued at $31,784,545 in the last 90 days. Insiders own 3.00% of the company’s stock.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $140.13 on Monday. The firm has a market capitalization of $30.21 billion, a price-to-earnings ratio of -21.86 and a beta of 1.13. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The business has a fifty day simple moving average of $158.58 and a 200 day simple moving average of $165.83. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same quarter in the prior year, the firm earned ($1.32) EPS. The firm’s quarterly revenue was up 152.6% on a year-over-year basis. Sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Jefferies Financial Group set a $269.00 price target on Insmed in a research report on Wednesday, December 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Leerink Partners reaffirmed an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Guggenheim reduced their price target on shares of Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Finally, Bank of America set a $203.00 price target on shares of Insmed in a research report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $207.52.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.